Episode 2 – MS treatment landscape part one: unmet needs
01 września 2025
In Episode 2 of the Illuminoz podcast series, Bianca Stadler speaks with Professor Luisa Klotz, a neuroimmunology expert, about the persistent challenges in multiple sclerosis care.
Despite major advances in MS therapies, key gaps remain—especially in treating disease progression, promoting neuroprotection, and enabling remyelination. Systemic barriers such as limited access, infrastructure constraints, and reimbursement issues continue to impact treatment decisions across Europe.
Discover how biosimilars could help bridge these gaps and expand access to high-efficacy therapies for patients in need.
Informacje o podcaście:
“Illuminoz talks 2025” podcast series:
Episode 12 – PML: what is it, and why is it relevant in MS?
dr Tobias Bopp,
Episode 11 – Introducing biosimilar natalizumab
dr Heinz Wiendl,
Episode 10 – Patient conversations part three: the patient perspective
Ellen Tutton,
Episode 9 – Patient conversations part two: the nurse perspective
karolinamalicka,
Episode 8 – Patient conversations part one: the neurologist perspective
dr Agne Straukiene,
Episode 7 – Lessons learned part two: the value of biosimilars in rheumatology
prof. Paul Emery,
Episode 6 – Lessons learned part one: the value of biosimilars in oncology
prof. Kai Hübel,
Episode 5 – Biosimilars and MS: improving access to high-efficacy treatment
dr Barbara Kornek,
Episode 4 – Treatment paradigms in MS: right patient, right treatment, right time
dr Laura Airas,
Episode 3 – MS treatment landscape part two: potential role of biosimilars
dr David Paling,
Episode 1 – Biosimilars: what are they, and why might they be important for MS?
dr Wallace Brownlee,
